复肝片治疗慢性乙型肝炎肝纤维化的临床观察

目的:为了观察中药复方制剂复肝片对慢性肝炎肝纤维化的治疗效果,对120例慢性肝炎肝纤维化的病例进行了临床观察。方法:120例慢性肝炎肝纤维化的病例分为复肝片治疗组和肝炎灵对照组各60例,观察治疗前后症状体征、肝功能、影像学指标、血清肝纤维化指标、肝脏组织学的变化情况,并将两组治疗结果进行比较。结果:治疗组总有效率88.33%,对照组总有效率68.33%,两组比较有显著性差异(P<0.01);两组治疗前后血清肝纤维化指标均有明显降低,与治疗前比较有非常显著的差异(P<0.01),治疗组与对照组比较有显著性差异(P<0.05);两组治疗前后影像学均有改善,治疗组门静脉内径、脾脏厚度治疗前后比较有非常显著的差异(P<0.01),门静脉流速、门静脉血流量有显著差异(P<0.05),与对照组比较有显著性差异(P<0.05);肝组织学由于病例少,未进行统计学处理。结论:临床观察证明复肝片对慢性肝炎肝纤维化有较好的治疗效果。

Clinical observation on treatment of chronic hepatitis Band hepatic fibrosis with Fugan Tablet

AIM: In order to observe the curative effect of Fugan Tablet on chronic hepatitis B and hepatic fibrosis,we held clinical observation of 120 cases of chronic hepatitis B and hepatic fibrosis. METHODS: 120 cases of chronic hepatitis B and hepatic fibrosis were divided into curative group with Fugan Tablet and control group with Hepatic Ling Injection,and the change of symptom,hepatic function,iconography index,hepatic fibrosis in serum and the hepatic histology were observed before and after the treatment,then the curative result of the two groups was compared. RESULTS: The total effective percentage of curative group was 88.33%,and the total effective percentage of control group was 68.33%.Comparing the two groups,the difference was obvious(P<0.01).The hepatic fibrosis in serum of both groups decreased obviously after the treatment,and the different was obvious compared with the index before the treatment(P<0.01),and there was obvious difference between curative group and control group(P<0.05).The iconography of both groups was improved after the treatment,and the venous inside diameter and splenic thickness of curative group had obvious difference before and after the treatment(P<0.01),and the velocity of flow and the blood flow in portal veil had obvious difference(P<0.05),and the difference was obvious in comparison with the curative group(P<0.05).Statisitic treatment of hepatic histology did not do because cases did not answer to. CONCLUSION: The clinical observation proves that Fugan Tablet has a better curative effect on chronic hepatitis B and hepatic fibrosis.